Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal Metastases: Multidisciplinary Consensus Document from the COLLISION Trial Group
Sanne Nieuwenhuizen(Amsterdam University Medical Centers), Hester J. Scheffer(Amsterdam UMC Location Vrije Universiteit Amsterdam), Koert P. de Jong(University of Padua), Mark C. Burgmans(Leiden University Medical Center), G Serafino(Jeroen Bosch Ziekenhuis), Arjen L. Diederik(Jeroen Bosch Ziekenhuis), Bart Geboers(Amsterdam University Medical Centers), Luca Aldrighetti(Vita-Salute San Raffaele University), Cornelis J.A. Haasbeek(Vrije Universiteit Amsterdam), Simeon J. S. Ruiter(University Medical Center Groningen), Floris J. Rietema(Noordwest Ziekenhuisgroep), Johan W. H. Kruimer(Flevoziekenhuis), Hasan H. Eker(Amsterdam University Medical Centers), Maarten W. Nijkamp(University Medical Center Groningen), G. Matthijs Kater(University Medical Center Groningen), Sarah Derks(Oncode Institute), Peter van Duijvendijk(Gelre Hospitals), Rutger‐Jan Swijnenburg(Amsterdam University Medical Centers), Francesco De Cobelli(Vita-Salute San Raffaele University), Marleen C. A. M. Melenhorst(Maine Farmland Trust), Fons H. Potters(Isala), Mariëlle M.E. Coolsen(Maastricht University Medical Centre), Mark Arntz(Radboud University Nijmegen), Mark A. Meier(Isala), Jurgen J. Fütterer(University of Twente), Kathelijn S. Versteeg(Amsterdam University Medical Centers), Wouter K. G. Leclercq(Radboud University Nijmegen), Joris I. Erdmann(Amsterdam University Medical Centers), Alette H. Ruarus(Amsterdam University Medical Centers), Bente A. T. van den Bemd(Amsterdam University Medical Centers), Geert Kazemier(Amsterdam Neuroscience), Warner Prevoo(The Netherlands Cancer Institute), Robbert S. Puijk(Amsterdam University Medical Centers), A. Bruynzeel(Amsterdam University Medical Centers), Cornelis H.C. Dejong(Maastricht University), Florentine E. F. Timmer(Dutch Cancer Society), Peter B. van den Boezem(Radboud University Nijmegen), Eric R. Manusama, Christiaan van der Leij(Maastricht University), Gerie Groot(Ziekenhuis Gelderse Vallei), Barbara M. Zonderhuis(Amsterdam Neuroscience), Johannes H.W. de Wilt(Radboud University Nijmegen), Evelien A. C. Schouten(Amsterdam University Medical Centers), Anton F. Engelsman(The University of Sydney), Jan-Jaap Janssen(Radboud University Nijmegen), Jan J.J. de Vries(Amsterdam University Medical Centers), Karin Nielsen(Amsterdam University Medical Centers), Colin Sietses(Amsterdam UMC Location Vrije Universiteit Amsterdam), Bram B. van der Meijs(Amsterdam University Medical Centers), Ted Vink(Medisch Centrum Leeuwarden)
Cited by 109
Related Papers
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.2k
Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial
|The Lancet|2017|715
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma
|Transplantation|2015|417
Irreversible Electroporation for Nonthermal Tumor Ablation in the Clinical Setting: A Systematic Review of Safety and Efficacy
|Journal of Vascular and Interventional Radiology|2014|401